JAKARTA - PT Biofarma through its subsidiary Kimia Farma has signed a Memorandum of Understanding (MoU) with Sinophram to develop and increase business potential related to the Cooperation in the Development of Drug Baku Materials (BBO).
In addition to BBO, the development of Traditional Chinese Medicine (TCM) and Project Platform TB is also contained in the MoU sheet.
The Memorandum of Understanding was signed by KAEF President Director David Utama and Sinopharm International President Zhou Song and witnessed by the President Director of Pharmaceutical SOE Holding, Honesti Basyir and Chairman of Sinopharm, Liu Jingzhen in Beijing, China last March.
"With the signing of the MOU between KAEF and Sinopharm, this is certainly a good opportunity for Biofarma Group to continue to maintain the nation's health resilience," said the President Director of the Pharmaceutical BUMN Holding, Honesti Basyir in a press release on Saturday.
"This is in line with one of the main programs of the Ministry of Health, namely increasing the resilience of pharmaceuticals and medical devices," Honesti added.
"One of the agenda for increasing the resilience of the pharmaceutical sector is to increase the fulfillment of the needs of Drug Baku Materials (BBO)/Active Pharmaceutical Inngredients (API) for chemicals, biological products, vaccines, domestic production. Bio Farma's IndoVac vaccine is one of the tangible results of the independence of the national pharmaceutical industry with a Domestic Component Level (TKDN) of nine percent," he said.
KAEF President Director David Utama said that this agreement was a continuation of the collaboration between Kimia Farma and Sinopharm which had been well established during the handling of COVID-19.
"Kimia Farma supports national health resilience, one of which is by strengthening and accelerating Drug Baku Materials (BBO). Currently Kimia Farma has produced 14 BBOs and we will continue to improve," said David.
Furthermore, David said that this agreement is also a form of bilateral relations between the two countries to improve and encourage the transformation of the Health industry.
Biofarma Group has established various global collaborations as an effort to increase national pharmaceutical health resilience.
"Currently, Biofarma Group products and services have been used in more than 150 countries. In addition, we have collaborated with various global companies," Honesti said.
The global company includes the British Pharmaceutical Company, Profactor Pharma for the development of blood products Recombinant Factor VIII, the collaboration between Bio Farma with Google Cloud, Fitbit and Connectedlife on new digital health initiatives, and cooperation with MSD to locally produce 4-valent human papillomavirus (HPV) vaccines, as an effort to improve the quality of public health through synergy, innovation and collaboration, "said Honesti.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
